Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis

Current Pharmaceutical Design

Volumn 17, Issue 3, 2011, Pages 204-214

  Seaborn, Tommy ^a,b   Masmoudi Kouli, Olfa ^c   Fournier, Alain ^d,e   Vaudry, Hubert ^b,e   Vaudry, David ^b,e  

^a LAVAL UNIVERSITY   (Canada)

^b Université de Rouen   (France)

^c FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^d INRS INSTITUT ARMAND FRAPPIER   (Canada)

^e UNIVERSITÉ DE ROUEN   (France)

Author keywords

Apoptosis; Bcl 2; Caspase; Neuroprotection; PAC1; PACAP

Indexed keywords

ACETYL [ALA15,ALA20] HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 38 PROPYLAMIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE; CASPASE 3; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME C; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN KINASE C; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN DEVELOPMENT; BRAIN ISCHEMIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; DEGENERATIVE DISEASE; DRUG BINDING SITE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; EYE PROTECTION; HEART FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; NERVE CELL NECROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; RETINA INJURY; SECOND MESSENGER; SPINAL CORD INJURY; STROKE; TRAUMATIC BRAIN INJURY;

ANIMALS; APOPTOSIS; CASPASE 3; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; SIGNAL TRANSDUCTION;

EID: 79958231721     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795049679     Document Type: Article

References (190)

1. Lockshin RA, Williams CM. Programmed Cell Death--I. Cytology of Degeneration in the Intersegmental Muscles of the Pernyi Silkmoth. Journal of insect physiology 1965; 11: 123-33.
2. Lockshin RA, Zakeri Z. Programmed cell death and apoptosis: origins of the theory. Nature reviews. Molecular cell biology 2001; 2: 545-50.
3. Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/CED-3 protease nomenclature. Cell 1996; 87: 171.
4. Eckhart L, Ballaun C, Hermann M, et al. Identification of novel mammalian caspases reveals an important role of gene loss in shaping the human caspase repertoire. Molecular biology and evolution 2008; 25: 831-41.
5. Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. The Journal of clinical investigation 2005; 115: 2665-72.
6. Liu H, Chang DW, Yang X. Interdimer processing and linearity of procaspase-3 activation. A unifying mechanism for the activation of initiator and effector caspases. The Journal of biological chemistry 2005; 280: 11578-82.
7. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995; 81: 801-9.
8. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6.
9. Kumar S. The apoptotic cysteine protease CPP32. The international journal of biochemistry & cell biology 1997; 29: 393-6.
10. Kuida K, Zheng TS, Na S, et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 1996; 384: 368-72.
11. Le DA, Wu Y, Huang Z, et al. Caspase activation and neuroprotection in caspase-3- deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 15188-93.
12. Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochemical and biophysical research communications 1989; 164: 567-74.
13. Miyata A, Jiang L, Dahl RD, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochemical and biophysical research communications 1990; 170: 643-8.
14. Gonzalez BJ, Basille M, Vaudry D, Fournier A, Vaudry H. [Pituitary adenylate cyclase-activating polypeptide]. Annales d'endocrinologie 1998; 59: 364-405.
15. Vaudry D, Gonzalez BJ, Basille M, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacological reviews 2000; 52: 269-324.
16. Bourgault S, Vaudry D, Dejda A, et al. Pituitary adenylate cyclaseactivating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide. Current medicinal chemistry 2009; 16: 4462-80.
17. Shintani N, Mori W, Hashimoto H, et al. Defects in reproductive functions in PACAP-deficient female mice. Regulatory peptides 2002; 109: 45-8.
18. Matsuda K, Maruyama K, Miura T, Uchiyama M, Shioda S. Anorexigenic action of pituitary adenylate cyclase-activating polypeptide (PACAP) in the goldfish: feeding-induced changes in the expression of mRNAs for PACAP and its receptors in the brain, and locomotor response to central injection. Neuroscience letters 2005; 386: 9-13.
19. Araki N, Takagi K. Relaxant effect of pituitary adenylate cyclaseactivating polypeptide on guinea-pig tracheal smooth muscle. European journal of pharmacology 1992; 216: 113-7.
20. Gasz B, Racz B, Roth E, et al. Pituitary adenylate cyclase activating polypeptide protects cardiomyocytes against oxidative stressinduced apoptosis. Peptides 2006; 27: 87-94.
21. Ganea D, Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Critical reviews in oral biology and medicine: an official publication of the American Association of Oral Biologists 2002; 13: 229-37.
22. Moody TW, Zia F, Makheja A. Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells. Peptides 1993; 14: 241-6.
23. Arimura A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. The Japanese journal of physiology 1998; 48: 301-31.
24. Kawaguchi C, Isojima Y, Shintani N, et al. PACAP-deficient mice exhibit light parameter-dependent abnormalities on nonvisual photoreception and early activity onset. PloS one 2010; 5: e9286.
25. Dejda A, Jolivel V, Bourgault S, et al. Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: a better understanding towards therapeutic applications in neurodegenerative diseases. Journal of molecular neuroscience: MN 2008; 36: 26-37.
26. Masuo Y, Tokito F, Matsumoto Y, Shimamoto N, Fujino M. Ontogeny of pituitary adenylate cyclase-activating polypeptide (PACAP) and its binding sites in the rat brain. Neuroscience letters 1994; 170: 43-6.
27. Basille M, Gonzalez BJ, Fournier A, Vaudry H. Ontogeny of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in the rat cerebellum: a quantitative autoradiographic study. Brain research. Developmental brain research 1994; 82: 81-9.
28. Basille M, Gonzalez BJ, Leroux P, et al. Localization and characterization of PACAP receptors in the rat cerebellum during development: evidence for a stimulatory effect of PACAP on immature cerebellar granule cells. Neuroscience 1993; 57: 329-38.
29. Campbell RM, Scanes CG. Evolution of the growth hormonereleasing factor (GRF) family of peptides. Growth Regul 1992; 2: 175-91.
30. Canonico PL, Copani A, D'Agata V, et al. Activation of pituitary adenylate cyclase-activating polypeptide receptors prevents apoptotic cell death in cultured cerebellar granule cells. Ann N Y Acad Sci 1996; 805: 470-2.
31. Cavallaro S, Copani A, D'Agata V, et al. Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. Mol Pharmacol 1996; 50: 60-6.
32. Chang JY, Korolev VV, Wang JZ. Cyclic AMP and pituitary adenylate cyclase-activating polypeptide (PACAP) prevent programmed cell death of cultured rat cerebellar granule cells. Neurosci Lett 1996; 206: 181-4.
33. Gonzalez BJ, Basille M, Vaudry D, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts. Neuroscience 1997; 78: 419-30.
34. Villalba M, Bockaert J, Journot L. Pituitary adenylate cyclaseactivating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J Neurosci 1997; 17: 83-90.
35. Vaudry D, Gonzalez BJ, Basille M, et al. The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32. Proceedings of the National Academy of Sciences of the United States of America 2000; 97: 13390-5.
36. Allais A, Burel D, Isaac ER, et al. Altered cerebellar development in mice lacking pituitary adenylate cyclase-activating polypeptide. The European journal of neuroscience 2007; 25: 2604-18.
37. Vaudry D, Gonzalez BJ, Basille M, Fournier A, Vaudry H. Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 9415-20.
38. Ito Y, Arakawa M, Ishige K, Fukuda H. Comparative study of survival signal withdrawal- and 4-hydroxynonenal-induced cell death in cerebellar granule cells. Neurosci Res 1999; 35: 321-7.
39. Vaudry D, Pamantung TF, Basille M, et al. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur J Neurosci 2002; 15: 1451-60.
40. Vaudry D, Rousselle C, Basille M, et al. Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proc Natl Acad Sci USA 2002; 99: 6398-403.
41. Falluel-Morel A, Aubert N, Vaudry D, et al. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells. J Neurochem 2004; 91: 1231-43.
42. Vaudry D, Falluel-Morel A, Basille M, et al. Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. J Neurosci Res 2003; 72: 303-16.
43. Vaudry D, Falluel-Morel A, Leuillet S, Vaudry H, Gonzalez BJ. Regulators of cerebellar granule cell development act through specific signaling pathways. Science 2003; 300: 1532-4.
44. Aubert N, Vaudry D, Falluel-Morel A, et al. PACAP prevents toxicity induced by cisplatin in rat and primate neurons but not in proliferating ovary cells: Involvement of the mitochondrial apoptotic pathway. Neurobiol Dis 2008.
45. Kienlen Campard P, Crochemore C, Rene F, et al. PACAP type I receptor activation promotes cerebellar neuron survival through the cAMP/PKA signaling pathway. DNA Cell Biol 1997; 16: 323-33.
46. Obara Y, Horgan AM, Stork PJ. The requirement of Ras and Rap1 for the activation of ERKs by cAMP, PACAP, and KCl in cerebellar granule cells. J Neurochem 2007; 101: 470-82.
47. Vaudry D, Basille M, Anouar Y, et al. The neurotrophic activity of PACAP on rat cerebellar granule cells is associated with activation of the protein kinase A pathway and c-fos gene expression. Annals of the New York Academy of Sciences 1998; 865: 92-9.
48. Aubert N, Falluel-Morel A, Vaudry D, et al. PACAP and C2-ceramide generate different AP-1 complexes through a MAPkinase- dependent pathway: involvement of c-Fos in PACAPinduced Bcl-2 expression. J Neurochem 2006; 99: 1237-50.
49. Botia B, Basille M, Allais A, et al. Neurotrophic effects of PACAP in the cerebellar cortex. Peptides 2007; 28: 1746-52.
50. Falluel-Morel A, Aubert N, Vaudry D, et al. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells. Journal of neurochemistry 2004; 91: 1231-43.
51. Zerr P, Feltz A. Forskolin blocks the transient K current of rat cerebellar granule neurons. Neurosci Lett 1994; 181: 153-7.
52. Mei YA, Vaudry D, Basille M, et al. PACAP inhibits delayed rectifier potassium current via a cAMP/PKA transduction pathway: evidence for the involvement of I k in the anti-apoptotic action of PACAP. Eur J Neurosci 2004; 19: 1446-58.
53. Bhave SV, Hoffman PL. Phosphatidylinositol 3'-OH kinase and protein kinase A pathways mediate the anti-apoptotic effect of pituitary adenylyl cyclase-activating polypeptide in cultured cerebellar granule neurons: modulation by ethanol. J Neurochem 2004; 88: 359-69.
54. Botia B, Seyer D, Ravni A, et al. Peroxiredoxin 2 is involved in the neuroprotective effects of PACAP in cultured cerebellar granule neurons. Journal of molecular neuroscience: MN 2008; 36: 61-72.
55. Botia B, Jolivel V, Burel D, et al. Neuroprotective Effects of PACAP Against Ethanol-Induced Toxicity in the Developing Rat Cerebellum. Neurotoxicity research 2010; in press.
56. Aubert N, Basille M, Falluel-Morel A, et al. Molecular, cellular, and functional characterizations of pituitary adenylate cyclaseactivating polypeptide and its receptors in the cerebellum of New and Old World monkeys. The Journal of comparative neurology 2007; 504: 427-39.
57. Favrais G, Couvineau A, Laburthe M, Gressens P, Lelievre V. Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge. Peptides 2007; 28: 1727-37.
58. Rangon CM, Goursaud S, Medja F, et al. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice. J Pharmacol Exp Ther 2005; 314: 745-52.
59. Martin JL, Gasser D, Magistretti PJ. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide potentiate cfos expression induced by glutamate in cultured cortical neurons. J Neurochem 1995; 65: 1-9.
60. Morio H, Tatsuno I, Hirai A, Tamura Y, Saito Y. Pituitary adenylate cyclase-activating polypeptide protects rat-cultured cortical neurons from glutamate-induced cytotoxicity. Brain Res 1996; 741: 82-8.
61. Liu GJ, Madsen BW. PACAP38 modulates activity of NMDA receptors in cultured chick cortical neurons. J Neurophysiol 1997; 78: 2231-4.
62. Liu GJ, Madsen BW. Modulatory action of PACAP27 on NMDA receptor channel activity in cultured chick cortical neurons. Brain Res 1998; 791: 290-4.
63. Kong LY, Maderdrut JL, Jeohn GH, Hong JS. Reduction of lipopolysaccharide-induced neurotoxicity in mixed cortical neuron/ glia cultures by femtomolar concentrations of pituitary adenylate cyclase-activating polypeptide. Neuroscience 1999; 91: 493-500.
64. Sanchez A, Rao HV, Grammas P. PACAP38 protects rat cortical neurons against the neurotoxicity evoked by sodium nitroprusside and thrombin. Regul Pept 2009; 152: 33-40.
65. Frechilla D, Garcia-Osta A, Palacios S, Cenarruzabeitia E, Del Rio J. BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons. Neuroreport 2001; 12: 919-23.
66. Shintani N, Suetake S, Hashimoto H, et al. Neuroprotective action of endogenous PACAP in cultured rat cortical neurons. Regul Pept 2005; 126: 123-8.
67. Yaka R, He DY, Phamluong K, Ron D. Pituitary adenylate cyclaseactivating polypeptide (PACAP(1-38)) enhances N-methyl-Daspartate receptor function and brain-derived neurotrophic factor expression via RACK1. J Biol Chem 2003; 278: 9630-8.
68. Delcourt N, Thouvenot E, Chanrion B, et al. PACAP type I receptor transactivation is essential for IGF-1 receptor signalling and antiapoptotic activity in neurons. The EMBO journal 2007; 26: 1542-51.
69. Jolivel V, Basille M, Aubert N, et al. Distribution and functional characterization of pituitary adenylate cyclase-activating polypeptide receptors in the brain of non-human primates. Neuroscience 2009; 160: 434-51.
70. Reglodi D, Somogyvari-Vigh A, Vigh S, Maderdrut JL, Arimura A. Neuroprotective effects of PACAP38 in a rat model of transient focal ischemia under various experimental conditions. Annals of the New York Academy of Sciences 2000; 921: 119-28.
71. Reglodi D, Tamas A, Somogyvari-Vigh A, et al. Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides 2002; 23: 2227-34.
72. Uchida D, Arimura A, Somogyvari-Vigh A, Shioda S, Banks WA. Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain research 1996; 736: 280-6.
73. Chen Y, Samal B, Hamelink CR, et al. Neuroprotection by endogenous and exogenous PACAP following stroke. Regulatory peptides 2006; 137: 4-19.
74. Ohtaki H, Nakamachi T, Dohi K, et al. Pituitary adenylate cyclaseactivating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 7488-93.
75. Stumm R, Kolodziej A, Prinz V, et al. Pituitary adenylate cyclaseactivating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. Journal of neurochemistry 2007; 103: 1666-81.
76. Stetler RA, Gao Y, Zukin RS, et al. Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 3204-9.
77. Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. Clinical neurology and neurosurgery 2009; 111: 483-95.
78. Horvath G, Reglodi D, Opper B, et al. Effects of PACAP on the oxidative stress-induced cell death in chicken pinealocytes is influenced by the phase of the circadian clock. Neuroscience letters 2010; 484: 148-52.
79. Vaudry D, Pamantung TF, Basille M, et al. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. The European journal of neuroscience 2002; 15: 1451-60.
80. Armstrong BD, Abad C, Chhith S, et al. Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide. Neuroscience 2008; 151: 63-73.
81. Makela J, Koivuniemi R, Korhonen L, Lindholm D. Interferongamma produced by microglia and the neuropeptide PACAP have opposite effects on the viability of neural progenitor cells. PloS one 2010; 5: e11091.
82. Suk K, Park JH, Lee WH. Neuropeptide PACAP inhibits hypoxic activation of brain microglia: a protective mechanism against microglial neurotoxicity in ischemia. Brain research 2004; 1026: 151-6.
83. Vaudry D, Chen Y, Hsu CM, Eiden LE. PC12 cells as a model to study the neurotrophic activities of PACAP. Annals of the New York Academy of Sciences 2002; 971: 491-6.
84. Onoue S, Ohshima K, Endo K, Yajima T, Kashimoto K. PACAP protects neuronal PC12 cells from the cytotoxicity of human prion protein fragment 106-126. FEBS letters 2002; 522: 65-70.
85. Onoue S, Endo K, Ohshima K, Yajima T, Kashimoto K. The neuropeptide PACAP attenuates beta-amyloid (1-42)-induced toxicity in PC12 cells. Peptides 2002; 23: 1471-8.
86. Wang G, Qi C, Fan GH, Zhou HY, Chen SD. PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex I inhibitor, rotenone. FEBS letters 2005; 579: 4005-11.
87. Dejda A, Chan P, Seaborn T, et al. Involvement of stathmin 1 in the neurotrophic effects of PACAP in PC12 cells. Journal of neurochemistry 2010; 114: 1498-510.
88. Takei N, Skoglosa Y, Lindholm D. Neurotrophic and neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on mesencephalic dopaminergic neurons. Journal of neuroscience research 1998; 54: 698-706.
89. Yang S, Yang J, Yang Z, et al. Pituitary adenylate cyclaseactivating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress. J Pharmacol Exp Ther 2006; 319: 595-603.
90. Reglodi D, Fabian Z, Tamas A, et al. Effects of PACAP on in vitroand in vivo neuronal cell death, platelet aggregation, and production of reactive oxygen radicals. Regulatory peptides 2004; 123: 51-9.
91. Tamas A, Lubics A, Lengvari I, Reglodi D. Protective effects of PACAP in excitotoxic striatal lesion. Annals of the New York Academy of Sciences 2006; 1070: 570-4.
92. Dogrukol-Ak D, Kumar VB, Ryerse JS, et al. Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 2009; 29: 411-22.
93. van Landeghem FK, Weiss T, Oehmichen M, von Deimling A. Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans. Acta Neuropathol 2007; 113: 683-93.
94. Farkas O, Tamas A, Zsombok A, et al. Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury. Regulatory peptides 2004; 123: 69-75.
95. Tamas A, Zsombok A, Farkas O, et al. Postinjury administration of pituitary adenylate cyclase activating polypeptide (PACAP) attenuates traumatically induced axonal injury in rats. Journal of neurotrauma 2006; 23: 686-95.
96. Kovesdi E, Tamas A, Reglodi D, et al. Posttraumatic administration of pituitary adenylate cyclase activating polypeptide in central fluid percussion injury in rats. Neurotoxicity research 2008; 13: 71-8.
97. Chen WH, Tzeng SF. Pituitary adenylate cyclase-activating polypeptide prevents cell death in the spinal cord with traumatic injury. Neuroscience letters 2005; 384: 117-21.
98. May V, Lutz E, MacKenzie C, et al. Pituitary adenylate cyclaseactivating polypeptide (PACAP)/PAC1HOP1 receptor activation coordinates multiple neurotrophic signaling pathways: Akt activation through phosphatidylinositol 3-kinase gamma and vesicle endocytosis for neuronal survival. The Journal of biological chemistry 2010; 285: 9749-61.
99. Tatsuno I, Gottschall PE, Arimura A. Specific binding sites for pituitary adenylate cyclase activating polypeptide (PACAP) in rat cultured astrocytes: molecular identification and interaction with vasoactive intestinal peptide (VIP). Peptides 1991; 12: 617-21.
100. Ashur-Fabian O, Giladi E, Brenneman DE, Gozes I. Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. J Mol Neurosci 1997; 9: 211-222.
101. Grimaldi M, Cavallaro S. Functional and molecular diversity of PACAP/VIP receptors in cortical neurons and type I astrocytes. Eur J Neurosci 1999; 11: 2767-72.
102. Hashimoto H, Kunugi A, Arakawa N, et al. Possible involvement of a cyclic AMP-dependent mechanism in PACAP-induced proliferation and ERK activation in astrocytes. Biochem Biophys Res Commun 2003; 311: 337-43.
103. Jozwiak-Bebenista M, Dejda A, Nowak JZ. Effects of PACAP, VIP and related peptides on cyclic AMP formation in rat neuronaland astrocyte cultures and cerebral cortical slices. Pharmacol Rep 2007; 59: 414-20.
104. Masmoudi O, Gandolfo P, Leprince J, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates endozepine release from cultured rat astrocytes via a PKA-dependent mechanism. FASEB J 2003; 17: 17-27.
105. Dejda A, Jozwiak-Bebenista M, Nowak JZ. PACAP, VIP, and PHI: effects on AC-, PLC-, and PLD-driven signaling systems in the primary glial cell cultures. Ann N Y Acad Sci 2006; 1070: 220-5.
106. Tatsuno I, Arimura A. Pituitary adenylate cyclase-activating polypeptide (PACAP) mobilizes intracellular free calcium in cultured rat type-2, but not type-1, astrocytes. Brain Res 1994; 662: 1-10.
107. Morio H, Tatsuno I, Hirai A, Tamura Y, Saito Y. Pituitary adenylate cyclase-activating polypeptide protects rat-cultured cortical neurons from glutamate-induced cytotoxicity. Brain research 1996; 741: 82-8.
108. Brenneman DE. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Peptides 2007; 28: 1720-6.
109. Dejda A, Sokolowska P, Nowak JZ. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol Rep 2005; 57: 307-20.
110. Masmoudi-Kouki O, Gandolfo P, Castel H, et al. Role of PACAP and VIP in astroglial functions. Peptides 2007; 28: 1753-60.
111. Shioda S, Ohtaki H, Suzuki R, et al. Prevention of delayed neuronal cell death by PACAP and its molecular mechanism. Nippon Yakurigaku Zasshi 2004; 123: 243-52.
112. Stumm R, Kolodziej A, Prinz V, et al. Pituitary adenylate cyclaseactivating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ ischemic damage. J Neurochem 2007; 103: 1666-81.
113. Shieh PC, Tsao CW, Li JS, et al. Role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the action of ginsenoside Rh2 against beta-amyloid-induced inhibition of rat brain astrocytes. Neurosci Lett 2008; 434: 1-5.
114. Masmoudi-Kouki O, Douiri S, Hamdi Y, et al. Pituitary adenylate cyclase-activating polypeptide protects astroglial cells against oxidative stress-induced apoptosis. Journal of neurochemistry 2011; in press.
115. Suzuki R, Arata S, Nakajo S, et al. Expression of the receptor for pituitary adenylate cyclase-activating polypeptide (PAC1-R) in reactive astrocytes. Brain Res Mol Brain Res 2003; 115: 10-20.
116. Nakamachi T, Nakamura K, Oshida K, et al. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Stimulates Proliferation of Reactive Astrocytes In Vitro. J Mol Neurosci 2010; in press.
117. Shoge K, Mishima HK, Saitoh T, et al. Attenuation by PACAP of glutamate-induced neurotoxicity in cultured retinal neurons. Brain research 1999; 839: 66-73.
118. Shoge K, Mishima HK, Saitoh T, et al. Attenuation by PACAP of glutamate-induced neurotoxicity in cultured retinal neurons. Brain Res 1999; 839: 66-73.
119. Silveira MS, Costa MR, Bozza M, Linden R. Pituitary adenylyl cyclase-activating polypeptide prevents induced cell death in retinal tissue through activation of cyclic AMP-dependent protein kinase. The Journal of biological chemistry 2002; 277: 16075-80.
120. Szabadfi K, Atlasz T, Horvath G, et al. Early postnatal enriched environment decreases retinal degeneration induced by monosodium glutamate treatment in rats. Brain research 2009; 1259: 107-12.
121. Babai N, Atlasz T, Tamas A, et al. Degree of damage compensation by various PACAP treatments in monosodium glutamateinduced retinal degeneration. Neurotoxicity research 2005; 8: 227-33.
122. Tamas A, Gabriel R, Racz B, et al. Effects of pituitary adenylate cyclase activating polypeptide in retinal degeneration induced by monosodium-glutamate. Neuroscience letters 2004; 372: 110-3.
123. Atlasz T, Szabadfi K, Reglodi D, et al. Effects of pituitary adenylate cyclase activating polypeptide and its fragments on retinal degeneration induced by neonatal monosodium glutamate treatment. Annals of the New York Academy of Sciences 2009; 1163: 348-52.
124. Racz B, Gallyas F, Jr., Kiss P, et al. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the PKA-Bad-14-3-3 signaling pathway in glutamate-induced retinal injury in neonatal rats. Neurotoxicity research 2007; 12: 95-104.
125. Racz B, Gallyas F, Jr., Kiss P, et al. The neuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involveinhibition of proapoptotic signaling pathways. Regulatory peptides 2006; 137: 20-6.
126. Atlasz T, Szabadfi K, Kiss P, et al. PACAP-mediated neuroprotection of neurochemically identified cell types in MSG-induced retinal degeneration. Journal of molecular neuroscience: MN 2008; 36: 97-104.
127. Seki T, Nakatani M, Taki C, et al. Neuroprotective effect of PACAP against kainic acid-induced neurotoxicity in rat retina. Annals of the New York Academy of Sciences 2006; 1070: 531-4.
128. Atlasz T, Babai N, Kiss P, et al. Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. General and comparative endocrinology 2007; 153: 108-14.
129. Atlasz T, Szabadfi K, Kiss P, et al. Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects. Annals of the New York Academy of Sciences 2010; 1200: 128-39.
130. Racz B, Gasz B, Gallyas F, Jr., et al. PKA-Bad-14-3-3 and Akt-Bad-14-3-3 signaling pathways are involved in the protective effects of PACAP against ischemia/reperfusion-induced cardiomyocyte apoptosis. Regulatory peptides 2008; 145: 105-15.
131. Racz B, Gasz B, Borsiczky B, et al. Protective effects of pituitary adenylate cyclase activating polypeptide in endothelial cells against oxidative stress-induced apoptosis. General and comparative endocrinology 2007; 153: 115-23.
132. Gasz B, Racz B, Roth E, et al. PACAP inhibits oxidative stressinduced activation of MAP kinase-dependent apoptotic pathway in cultured cardiomyocytes. Annals of the New York Academy of Sciences 2006; 1070: 293-7.
133. Racz B, Reglodi D, Horvath G, et al. Protective effect of PACAP against doxorubicin-induced cell death in cardiomyocyte culture. Journal of molecular neuroscience: MN 2010; 42: 419-27.
134. Mori H, Nakamachi T, Ohtaki H, et al. Cardioprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on Doxorubicin-induced cardiomyopathy in mice. Circulation journal: official journal of the Japanese Circulation Society 2010; 74: 1183-90.
135. Onoue S, Ohmori Y, Endo K, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. Eur J Biochem 2004; 271: 1757-67.
136. Doberer D, Gschwandtner M, Mosgoeller W, et al. Pulmonary and systemic effects of inhaled PACAP38 in healthy male subjects. European journal of clinical investigation 2007; 37: 665-72.
137. Delgado M, Garrido E, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptides (PACAP27) and PACAP38) protect CD4+CD8+thymocytes from glucocorticoid-induced apoptosis. Blood 1996; 87: 5152-61.
138. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. Journal of immunology 2000; 165: 114-23.
139. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression. Journal of immunology 2000; 164: 1200-10.
140. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-inducedapoptosis of mature T lymphocytes by inhibiting Fas ligand expression. J Immunol 2000; 164: 1200-10.
141. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3. Journal of immunology 2001; 166: 1028-40.
142. Gutierrez-Canas I, Rodriguez-Henche N, Bolanos O, et al. VIP and PACAP are autocrine factors that protect the androgen-independentprostate cancer cell line PC 3 from apoptosis induced by serum withdrawal. Br J Pharmacol 2003; 139: 1050-8.
143. Oka H, Jin L, Kulig E, Scheithauer BW, Lloyd RV. Pituitary adenylate cyclase-activating polypeptide inhibits transforming growth factor-beta1-induced apoptosis in a human pituitary adenoma cell line. Am J Pathol 1999; 155: 1893-900.
144. Lee J, Park HJ, Choi HS, et al. Gonadotropin stimulation of pituitary adenylate cyclase-activating polypeptide (PACAP) messenger ribonucleic acid in the rat ovary and the role of PACAP as a follicle survival factor. Endocrinology 1999; 140: 818-26.
145. Flaws JA, Kugu K, Trbovich AM, et al. Interleukin-1 betaconverting enzyme-related proteases (IRPs) and mammalian celldeath: dissociation of IRP-induced oligonucleosomal endonuclease activity from morphological apoptosis in granulosa cells of the ovarian follicle. Endocrinology 1995; 136: 5042-53.
146. Johnson AL. Intracellular mechanisms regulating cell survival in ovarian follicles. Animal reproduction science 2003; 78: 185-201.
147. Kanekar S, Gandham M, Lucero MT. PACAP protects against TNFalpha-induced cell death in olfactory epithelium and olfactory placodal cell lines. Molecular and cellular neurosciences 2010; 45: 345-54.
148. Somogyvari-Vigh A, Reglodi D. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Current pharmaceutical design 2004; 10: 2861-89.
149. Zhu L, Tamvakopoulos C, Xie D, et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide- (1-38). The Journal of biological chemistry 2003; 278: 22418-23.
150. Bourgault S, Vaudry D, Botia B, et al. Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 2008; 29: 919-32.
151. Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine- like attacks in patients with migraine without aura. Brain: a journal of neurology 2009; 132: 16-25.
152. Schytz HW, Olesen J, Ashina M. The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics 2010; 7: 191-6.
153. Deguil J, Jailloux D, Page G, et al. Neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in MPP+-induced alteration of translational control in Neuro-2a neuroblastoma cells. Journal of neuroscience research 2007; 85: 2017-25.
154. Hartfield PJ, Bilney AJ, Murray AW. Neurotrophic factors prevent ceramide-induced apoptosis downstream of c-Jun N-terminal kinase activation in PC12 cells. Journal of neurochemistry 1998; 71: 161-9.
155. Magnani E, Bettini E. Resazurin detection of energy metabolism changes in serum-starved PC12 cells and of neuroprotective agent effect. Brain research. Brain research protocols 2000; 5: 266-72.
156. Tanaka J, Koshimura K, Murakami Y, et al. Neuronal protection from apoptosis by pituitary adenylate cyclase-activating polypeptide. Regulatory peptides 1997; 72: 1-8.
157. Tomimatsu N, Arakawa Y. Survival-promoting activity of pituitary adenylate cyclase-activating polypeptide in the presence of phosphodiesterase inhibitors on rat motoneurons in culture: cAMPprotein kinase A-mediated survival. Journal of neurochemistry 2008; 107: 628-35.
158. Scharf E, May V, Braas KM, Shutz KC, Mao-Draayer Y. Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) regulate murine neural progenitor cell survival, proliferation, and differentiation. Journal of molecular neuroscience: MN 2008; 36: 79-88.
159. Erhardt NM, Sherwood NM. PACAP maintains cell cycling and inhibits apoptosis in chick neuroblasts. Molecular and cellular endocrinology 2004; 221: 121-34.
160. Ito Y, Arakawa M, Ishige K, Fukuda H. Comparative study of survival signal withdrawal- and 4-hydroxynonenal-induced cell death in cerebellar granule cells. Neuroscience research 1999; 35: 321-7.
161. Vaudry D, Falluel-Morel A, Basille M, et al. Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. Journal of neuroscience research 2003; 72: 303-16.
162. Aubert N, Vaudry D, Falluel-Morel A, et al. PACAP prevents toxicity induced by cisplatin in rat and primate neurons but not in proliferating ovary cells: involvement of the mitochondrial apoptotic pathway. Neurobiology of disease 2008; 32: 66-80.
163. Vaudry D, Rousselle C, Basille M, et al. Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 6398-403.
164. Bhave SV, Hoffman PL. Phosphatidylinositol 3'-OH kinase and protein kinase A pathways mediate the anti-apoptotic effect of pituitary adenylyl cyclase-activating polypeptide in cultured cerebellar granule neurons: modulation by ethanol. Journal of neurochemistry 2004; 88: 359-69.
165. Cavallaro S, Copani A, D'Agata V, et al. Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. Molecular pharmacology 1996; 50: 60-6.
166. Chang JY, Korolev VV, Wang JZ. Cyclic AMP and pituitary adenylate cyclase-activating polypeptide (PACAP) prevent programmed cell death of cultured rat cerebellar granule cells. Neuroscience letters 1996; 206: 181-4.
167. Journot L, Villalba M, Bockaert J. PACAP-38 protects cerebellar granule cells from apoptosis. Annals of the New York Academy of Sciences 1998; 865: 100-10.
168. Kienlen Campard P, Crochemore C, Rene F, et al. PACAP type I receptor activation promotes cerebellar neuron survival through the cAMP/PKA signaling pathway. DNA and cell biology 1997; 16: 323-33.
169. Tabuchi A, Funaji K, Nakatsubo J, et al. Inactivation of aconitase during the apoptosis of mouse cerebellar granule neurons induced by a deprivation of membrane depolarization. Journal of neuroscience research 2003; 71: 504-15.
170. Tabuchi A, Koizumi M, Nakatsubo J, Yaguchi T, Tsuda M. Involvement of endogenous PACAP expression in the activitydependent survival of mouse cerebellar granule cells. Neuroscience research 2001; 39: 85-93.
171. Villalba M, Bockaert J, Journot L. Concomitant induction of apoptosis and necrosis in cerebellar granule cells following serum and potassium withdrawal. Neuroreport 1997; 8: 981-5.
172. Shintani N, Suetake S, Hashimoto H, et al. Neuroprotective action of endogenous PACAP in cultured rat cortical neurons. Regulatory peptides 2005; 126: 123-8.
173. Brenneman DE, Hauser JM, Spong C, Phillips TM. Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity. Neuropeptides 2002; 36: 271-80.
174. Sanchez A, Rao HV, Grammas P. PACAP38 protects rat cortical neurons against the neurotoxicity evoked by sodium nitroprusside and thrombin. Regulatory peptides 2009; 152: 33-40.
175. Chung CY, Seo H, Sonntag KC, et al. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Human molecular genetics 2005; 14: 1709-25.
176. Han P, Lucero MT. Pituitary adenylate cyclase activating polypeptide reduces A-type K+ currents and caspase activity in cultured adult mouse olfactory neurons. Neuroscience 2005; 134: 745-56.
177. Hansel DE, May V, Eipper BA, Ronnett GV. Pituitary adenylyl cyclase-activating peptides and alpha-amidation in olfactory neurogenesis and neuronal survival in vitro. The Journal of neuroscience: the official journal of the Society for Neuroscience 2001; 21: 4625-36.
178. Pugh PC, Margiotta JF. PACAP support of neuronal survival requires MAPK- and activity-generated signals. Molecular and cellular neurosciences 2006; 31: 586-95.
179. Chang JY, Korolev VV. Cyclic AMP and sympathetic neuronal programmed cell death. Neurochemistry international 1997; 31: 161-7.
180. Przywara DA, Kulkarni JS, Wakade TD, Leontiev DV, Wakade AR. Pituitary adenylyl cyclase-activating polypeptide and nerve growth factor use the proteasome to rescue nerve growth factordeprived sympathetic neurons cultured from chick embryos. Journal of neurochemistry 1998; 71: 1889-97.
181. Dohi K, Mizushima H, Nakajo S, et al. Pituitary adenylate cyclaseactivating polypeptide (PACAP) prevents hippocampal neurons from apoptosis by inhibiting JNK/SAPK and p38 signal transduction pathways. Regulatory peptides 2002; 109: 83-8.
182. Shioda S, Ozawa H, Dohi K, et al. PACAP protects hippocampal neurons against apoptosis: involvement of JNK/SAPK signaling pathway. Annals of the New York Academy of Sciences 1998; 865: 111-7.
183. Reglodi D, Tamas A, Lubics A, Szalontay L, Lengvari I. Morphological and functional effects of PACAP in 6-hydroxydopamineinduced lesion of the substantia nigra in rats. Regulatory peptides 2004; 123: 85-94.
184. Tamas A, Lubics A, Szalontay L, Lengvari I, Reglodi D. Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Behavioural brain research 2005; 158: 221-9.
185. Gozes I, Bachar M, Bardea A, et al. Protection against developmental retardation in apolipoprotein E-deficient mice by a fattyneuropeptide: implications for early treatment of Alzheimer's disease. Journal of neurobiology 1997; 33: 329-42.
186. Reglodi D, Lubics A, Kiss P, et al. Effect of PACAP in 6-OHD Ainducedinjury of the substantia nigra in intact young and ovariectomized female rats. Neuropeptides 2006; 40: 265-74.
187. Reglodi D, Tamas A, Lengvari I, et al. Comparative study of the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson's disease. Annals of the New York Academy of Sciences 2006; 1070: 518-24.
188. Wang G, Pan J, Tan YY, et al. Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of K(ATP) subunits and D2 receptors in the striatum. Neuropeptides 2008; 42: 267-76.
189. Fang KM, Chen JK, Hung SC, et al. Effects of combinatorial treatment with pituitary adenylate cyclase activating peptide and human mesenchymal stem cells on spinal cord tissue repair. PloS one 2010; 5: e15299.
190. Atlasz T, Szabadfi K, Kiss P, et al. Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain research bulletin 2010; 81: 497-504.